

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Miriam Freimer
Deal Size : Inapplicable
Deal Type : Inapplicable
Zilucoplan for Severe gMG Exacerbations
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 14, 2025
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Miriam Freimer
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 24, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ZILBRYSQ® Now Available in The U.S. for Generalized Myasthenia Gravis
Details : Zilbrysq (zilucoplan), the first FDA-approved self-administered C5 complement inhibitor, treats generalized myasthenia gravis in anti-AChR antibody-positive adults.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilbrysq (zilucoplan) is a C5 inhibitor peptide drug candidate, which is currently being evaluated for the treatment of patients with AChR antibody-positive generalized myasthenia gravis.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilbrysq (zilucoplan) is a once-daily, SC, self-administered peptide inhibitor of complement component 5 (C5 inhibitor). As the only once-daily gMG target therapy for self-administration by adult patients with anti-AChR antibody-positive gMG.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
October 17, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zilucoplan is a Protein drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Myasthenia Gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
September 28, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RA101495 (zilucoplan) is a once-daily SC, self-administered peptide inhibitor of complement component 5, which is investigated for the treatment of adults with generalized myasthenia gravis.
Product Name : Zilbrysq
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Zilucoplan Sodium
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
